A comprehensive view of astrazeneca ab. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AstraZeneca and Avillion’s PT027 albuterol, budesonide rescue inhaler shows significant reduction in risk of severe exacerbation in patients with moderate to severe asthma in Phase 3 trial; asthma affects 25 million in US, 339 worldwide
Published: May 17, 2022 by Business Wire
Biotech Pulse: FDA approves earlier use of Enhertu from AstraZeneca, Daiichi for adults with metastatic breast cancer; AstraZeneca reports Farxiga hits goal in heart failure patients, and Ultomiris significantly reduces relapse of autoimmune disease
Published: May 11, 2022 by Benzinga
COVID-19 vaccine makers prepare for smaller booster vaccine market as demand for first shots falls; global booster shot market, including people over 50, adults with health risk factors or who work in high-risk occupations, estimated at 1.7 billion people
Published: May 10, 2022 by CE Noticias Financieras
AstraZeneca reports Q1 net profit down 75% from a year ago to US$388.0M, with revenue up 56% year-over-year to US$11.4B; revenue increase driven by US$1.1B sales in Q1 of COVID-19 vaccine Vaxzevria, oncology business growth, acquisition of US Alexion
Published: May 04, 2022 by SeeNews Pharmaceuticals
AstraZeneca building 570,000 square-foot, purpose-built R&D center in Cambridge, Massachusetts, to be completed in 2026; facility will house Alexion corporate headquarters, with Alexion’s R&D center of excellence remaining in New Haven, Connecticut
Published: May 03, 2022 by AstraZeneca AB

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count